Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …

Importance Anti–vascular endothelial growth factor (VEGF) therapy is commonly used to
treat numerous retinal conditions and appears safe, yet controversy remains regarding …

OBJECTIVE The expression of vascular endothelial growth factor (VEGF) is elevated in
diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants …

Objective To report the 2-year outcomes of the BOLT study, a prospective randomized
controlled trial evaluating intravitreous bevacizumab and modified Early Treatment Diabetic …

PURPOSE: To report the findings at 1 year of a study comparing repeated intravitreal
bevacizumab (ivB) and modified Early Treatment of Diabetic Retinopathy Study (ETDRS) …

Background Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age
population worldwide. Many observational and preclinical studies have implicated vascular …

Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the
center of the macula, represents the most common cause of vision loss in patients affected …

In the past years, the management of diabetic retinopathy (DR) relied primarily on a good
systemic control of diabetes mellitus, and as soon as the severity of the vascular lesions …

Purpose To assess the effectiveness and safety of combining intravitreal endothelial growth
factor inhibitor (anti-VEGF) and ocular corticosteroids for diabetic macular edema (DME) …

Diabetic retinopathy and diabetic macular edema comprise a major source of visual
disability throughout the developed world. The etiology and pathogenesis of macular edema …